Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with or without carboplatin for recurrent glioblastoma multiforme
ACTRN12610000915055Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Nov 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and carboplatin in glioblastoma (GBM) (6 arms), sponsored by University of Sydney. Primary endpoint: Progression-free survival. Started Nov 2010; status: completed.
02
Drugs
bevacizumabcarboplatin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12610000915055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000915055.